Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
Cadrenal Therapeutics Inc. Common Stock
CVKD | US
15.24
USD-2.02
-11.70%
CVKD | US
About Cadrenal Therapeutics Inc. Common Stock
Sector
Healthcare
Industry
Biotechnology
Earnings date
30/06/2024
As of date
21/10/2024
Close
15.24
Open
17.50
High
17.95
Low
15.00
Cadrenal Therapeutics Inc. operates as a clinical development biopharmaceutical company. The company focuses on developing Tecarfarin a novel therapy with orphan drug indication for the prevention of systemic thromboembolism of cardiac origin in patients with end-stage renal disease and atrial fibrillation. The company was incorporated in 2022 and is headquartered in Ponte Vedra Florida.
View LessCVKD | US
Risk
144.1
Sharpe
0.53
Luna's Score
46/100
Recommendation
Hold
Luna says (CVKD | US)
What's Working
Positive Momentum
Low Debt to Equity (< 0.25)
Low Debt to Asset (< 0.2)
What's not Working
Weakness based on declining price with high volume
High Short-term Volatility
High 6-Month Volatility (>65%)
High Current Volume and Negative 1-Day Return
Microcap (<300M USD)
Volatility Signals
Bullish: Stable Volatility (6-month <= 1-month volatility) is positive for the stock performance.
Risk Meter
10 days
130.6%1 month
144.1%3 months
126.4%6 months
100.5%Returns
Fundamental Ratios
PE
-
Fwd. PE
-
Price to book
5.11
Debt to equity
0.00
Debt to assets
0.00
Ent. to EBITDA
0.21
Ent. to rev.
-
PEG
-
Other Fundamentals
EBITDA
-6.63M
MarketCap
18.02M
MarketCap(USD)
18.02M
Div. yield
-
Op. margin
-
Erngs. growth
-
Rev. growth
-
Ret. on equity
-174.01
Short ratio
0.43
Short perc.
2.54
Market Sentiment (SMA and Price signals)
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bullish (SMA1M > SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
SMAs: Stock Price Trends
Range10D
6.76
Range1M
7.95
Range3M
17.57
Volumes: Market Activity
Rel. volume
2.15
Price X volume
1.91M
Peers
Diversifiers
Industry Comparison
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | 0.21 | - | Cheaper |
| Ent. to Revenue | - | - | - |
| PE Ratio | - | 41.03 | - |
| Price to Book | 5.11 | 15.55 | Cheaper |
| Dividend Yield | - | - | - |
| Std. Deviation (3M) | 126.38 | - | Riskier |
| Debt to Equity | 0.00 | -1.23 | Expensive |
| Debt to Assets | 0.00 | 0.25 | Cheaper |
| Market Cap | 18.02M | - | Emerging |
